234 related articles for article (PubMed ID: 24722496)
1. Can a selective PPARγ modulator improve glycemic control in patients with type 2 diabetes with fewer side effects compared with pioglitazone?
DePaoli AM; Higgins LS; Henry RR; Mantzoros C; Dunn FL;
Diabetes Care; 2014 Jul; 37(7):1918-23. PubMed ID: 24722496
[TBL] [Abstract][Full Text] [Related]
2. Selective modulation of PPARγ activity can lower plasma glucose without typical thiazolidinedione side-effects in patients with Type 2 diabetes.
Dunn FL; Higgins LS; Fredrickson J; DePaoli AM;
J Diabetes Complications; 2011; 25(3):151-8. PubMed ID: 20739195
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of adding pioglitazone or sitagliptin to patients with type 2 diabetes insufficiently controlled with metformin and a sulfonylurea.
Liu SC; Chien KL; Wang CH; Chen WC; Leung CH
Endocr Pract; 2013; 19(6):980-8. PubMed ID: 23807528
[TBL] [Abstract][Full Text] [Related]
4. Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study.
Kendall DM; Rubin CJ; Mohideen P; Ledeine JM; Belder R; Gross J; Norwood P; O'Mahony M; Sall K; Sloan G; Roberts A; Fiedorek FT; DeFronzo RA
Diabetes Care; 2006 May; 29(5):1016-23. PubMed ID: 16644631
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of the PPARγ partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel-group study in patients with type 2 diabetes on stable insulin therapy.
Henriksen K; Byrjalsen I; Qvist P; Beck-Nielsen H; Hansen G; Riis BJ; Perrild H; Svendsen OL; Gram J; Karsdal MA; Christiansen C;
Diabetes Metab Res Rev; 2011 May; 27(4):392-401. PubMed ID: 21328517
[TBL] [Abstract][Full Text] [Related]
6. Improved glycemic control with insulin glargine versus pioglitazone as add-on therapy to sulfonylurea or metformin in patients with uncontrolled type 2 diabetes mellitus.
Meneghini LF; Traylor L; Schwartz SL
Endocr Pract; 2010; 16(4):588-99. PubMed ID: 20350924
[TBL] [Abstract][Full Text] [Related]
7. Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus.
Kovacs CS; Seshiah V; Merker L; Christiansen AV; Roux F; Salsali A; Kim G; Stella P; Woerle HJ; Broedl UC;
Clin Ther; 2015 Aug; 37(8):1773-88.e1. PubMed ID: 26138864
[TBL] [Abstract][Full Text] [Related]
8. One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes.
Hanefeld M; Brunetti P; Schernthaner GH; Matthews DR; Charbonnel BH;
Diabetes Care; 2004 Jan; 27(1):141-7. PubMed ID: 14693980
[TBL] [Abstract][Full Text] [Related]
9. Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study.
Henry RR; Lincoff AM; Mudaliar S; Rabbia M; Chognot C; Herz M
Lancet; 2009 Jul; 374(9684):126-35. PubMed ID: 19515415
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of hydroxychloroquine in the treatment of type 2 diabetes mellitus: a double blind, randomized comparison with pioglitazone.
Pareek A; Chandurkar N; Thomas N; Viswanathan V; Deshpande A; Gupta OP; Shah A; Kakrani A; Bhandari S; Thulasidharan NK; Saboo B; Devaramani S; Vijaykumar NB; Sharma S; Agrawal N; Mahesh M; Kothari K
Curr Med Res Opin; 2014 Jul; 30(7):1257-66. PubMed ID: 24669876
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of taspoglutide versus pioglitazone in subjects with type 2 diabetes uncontrolled with sulphonylurea or sulphonylurea-metformin therapy: a randomized, double-blind study (T-emerge 6).
Pratley RE; Urosevic D; Boldrin M; Balena R;
Diabetes Obes Metab; 2013 Mar; 15(3):234-40. PubMed ID: 22958426
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized, placebo-controlled, 26-week trial in patients with type 2 diabetes.
Fonseca V; Staels B; Morgan JD; Shentu Y; Golm GT; Johnson-Levonas AO; Kaufman KD; Goldstein BJ; Steinberg H
J Diabetes Complications; 2013; 27(2):177-83. PubMed ID: 23116881
[TBL] [Abstract][Full Text] [Related]
13. Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study.
Abdul-Ghani M; Migahid O; Megahed A; Adams J; Triplitt C; DeFronzo RA; Zirie M; Jayyousi A
Diabetes Care; 2017 Mar; 40(3):325-331. PubMed ID: 28096223
[TBL] [Abstract][Full Text] [Related]
14. Linagliptin improved glycaemic control without weight gain or hypoglycaemia in patients with type 2 diabetes inadequately controlled by a combination of metformin and pioglitazone: a 24-week randomized, double-blind study.
Bajaj M; Gilman R; Patel S; Kempthorne-Rawson J; Lewis-D'Agostino D; Woerle HJ
Diabet Med; 2014 Dec; 31(12):1505-14. PubMed ID: 24824197
[TBL] [Abstract][Full Text] [Related]
15. A randomized clinical trial evaluating the safety and efficacy of sitagliptin added to the combination of sulfonylurea and metformin in patients with type 2 diabetes mellitus and inadequate glycemic control.
Moses RG; Round E; Shentu Y; Golm GT; O'neill EA; Gantz I; Engel SS; Kaufman KD; Goldstein BJ
J Diabetes; 2016 Sep; 8(5):701-11. PubMed ID: 26625270
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5.
Home PD; Shamanna P; Stewart M; Yang F; Miller M; Perry C; Carr MC
Diabetes Obes Metab; 2015 Feb; 17(2):179-87. PubMed ID: 25406730
[TBL] [Abstract][Full Text] [Related]
17. Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.
Roberts VL; Stewart J; Issa M; Lake B; Melis R
Clin Ther; 2005 Oct; 27(10):1535-47. PubMed ID: 16330290
[TBL] [Abstract][Full Text] [Related]
18. Addition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: a prospective, randomized trial.
Aljabri K; Kozak SE; Thompson DM
Am J Med; 2004 Feb; 116(4):230-5. PubMed ID: 14969650
[TBL] [Abstract][Full Text] [Related]
19. Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, parallel-group trial.
Tan M; Johns D; González Gálvez G; Antúnez O; Fabián G; Flores-Lozano F; Zúñiga Guajardo S; Garza E; Morales H; Konkoy C; Herz M;
Clin Ther; 2004 May; 26(5):680-93. PubMed ID: 15220012
[TBL] [Abstract][Full Text] [Related]
20. Management of cardiovascular risk factors with pioglitazone combination therapies in type 2 diabetes: an observational cohort study.
Rodríguez A; Reviriego J; Karamanos V; del Cañizo FJ; Vlachogiannis N; Drossinos V;
Cardiovasc Diabetol; 2011 Feb; 10():18. PubMed ID: 21314919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
